Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Eli Lilly and Company
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Institut Bergonié
Milton S. Hershey Medical Center
M.D. Anderson Cancer Center
Institut Bergonié
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eisai Inc.
Children's Oncology Group
Hutchmed
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
Stanford University
Children's Oncology Group
Sarcoma Alliance for Research through Collaboration
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Eisai Inc.
Massachusetts General Hospital
Children's Oncology Group
Northwestern University
BTG International Inc.
National Cancer Institute (NCI)
The Hospital for Sick Children
M.D. Anderson Cancer Center
Isofol Medical AB
National Cancer Institute (NCI)
Children's Oncology Group
Children's Hospital of Philadelphia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Celgene
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Wake Forest University Health Sciences
Insmed Incorporated
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)
Children's Oncology Group